about
Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayVariation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriersSystemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle.Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma developmentHLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study.IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis CHepatocellular carcinoma: towards personalized medicine.Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current.Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.Differences in serum microRNA profiles in hepatitis B and C virus infection.Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy.Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
P50
Q28548426-63048928-42D3-48DD-BF47-9FB5FA83954EQ28943479-A7F71AD8-76AE-41B7-AB26-46AC65883A70Q33379418-120A965D-3857-49F9-818D-C55DB60F3B5AQ33622970-9CDDD5B6-C6AE-4DC1-93A2-6F791A19BE13Q34045308-3E8A7804-7BBE-4EEC-B924-DD74A3B0A45FQ34164822-35096F27-6C34-4811-91F0-67D2DE5A4ACAQ34455269-8F71C6CA-043B-4228-97D5-42FB2A28B949Q34755326-F1B5F607-1B81-4B1F-8265-F63CBEF41FB6Q35078358-E5841ABC-6934-493E-8464-5FD213CCDC12Q35838595-F99A8FA0-010F-4DF7-B0D3-31C9CFFC382EQ37984653-B9D6A032-1254-4B8E-874C-EB19133823A5Q38423306-C3BDA273-7490-414E-8D9B-5FCEFA6C8EF7Q38962121-B177CF34-7AB0-4A1E-A12D-D33F82CA494DQ39164701-25074074-7717-4A9B-A5B7-4669A08CDA09Q40087272-F668A242-92A5-4282-97FF-91857DC4918FQ40121081-6DBFCEB8-3985-4330-8659-F783BA5182A3Q40127647-E408929A-DFEB-4B6B-A8A9-732E514CCA2CQ40142985-DBEEE2F0-1824-4EA4-8597-0BDEE2C2314BQ40163221-68E8E1A7-9E2A-4426-B282-073CD521DA73Q40260177-B423A90C-F87C-49C5-973B-94F7CE50F429Q40351862-7DC18220-0496-446E-B2CF-94016D45EFAFQ40484179-B3E29A3D-AE19-4EDA-8548-B8DB245EBABCQ40491437-545D34F0-5A85-4A98-8847-09401A89AF2BQ40533002-D0836FCD-8005-422D-995A-380FAB00C9F5Q40539146-A792EB57-C1DC-45A7-A6B9-CF33C973F274Q40579878-9EF4AD4B-61E2-4864-A394-5B125B45839FQ40827559-0C05E479-3954-45EB-9513-D7F0D29B1082Q40903867-4196B588-7BFF-4F79-B5F4-9EF144F9C19EQ40912377-16AA11E5-4AA5-44E8-B7B5-A5D304DBF3D4Q40931494-DB83A067-7057-4FB5-A7F3-F925356CFEB8Q41001059-716A83A0-89A8-4593-A18A-5D0CB9F281AEQ41350762-E710CADD-A9F0-4C4C-AF07-60195178A21CQ41632526-61849894-3301-4A19-94FF-1E7438941D23Q42201301-E9529141-6035-473D-A593-B19C4F4B2AF4Q42211518-DD43401E-7FCD-4400-B67A-045A339CE203Q42212457-EA7698D2-8D7E-403C-9775-99AD4604E334Q42218316-38880872-6F88-4C82-AB3B-BF6FF24FA68BQ42230392-3920AC80-6447-4AE7-AECC-BE890731C894Q42245807-82D9E6F6-B6B3-4F2D-9677-2A5091299498Q42247557-F74925E2-65DC-488E-BDB2-81A74919FDB9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daiki Miki
@ast
Daiki Miki
@en
Daiki Miki
@es
Daiki Miki
@nl
Daiki Miki
@sl
type
label
Daiki Miki
@ast
Daiki Miki
@en
Daiki Miki
@es
Daiki Miki
@nl
Daiki Miki
@sl
prefLabel
Daiki Miki
@ast
Daiki Miki
@en
Daiki Miki
@es
Daiki Miki
@nl
Daiki Miki
@sl
P106
P31
P496
0000-0002-6505-9826